Skip to contentV
Vistagen Therapeutics, Inc.
V
VTGNVistagen Therapeutics, Inc. Q1 2019 · 10-Q
Revenue—
Net Income-$4.21M-$4.21MN/M vs Q1 2018 EPS Diluted-$0.20-$0.20N/M vs Q1 2018 Operating Income-$4,210,000N/M Operating Cash Flow-$3,135,300N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
ended Jun 30, 2018 · filed Aug 14, 2018 · 45 d after period end